Tonsil explants as a human in vitro model to study vaccine responses

Front Immunol. 2024 Sep 17:15:1425455. doi: 10.3389/fimmu.2024.1425455. eCollection 2024.

Abstract

Introduction: Vaccination is one of the most effective infection prevention strategies. Viruses with high mutation rates -such as influenza- escape vaccine-induced immunity and represent significant challenges to vaccine design. Influenza vaccine strain selection is based on circulating strains and immunogenicity testing in animal models with limited predictive outcomes for vaccine effectiveness in humans.

Methods: We developed a human in vitro vaccination model using human tonsil tissue explants cultured in 3D perfusion bioreactors to be utilized as a platform to test and improve vaccines.

Results: Tonsils cultured in bioreactors showed higher viability, metabolic activity, and more robust immune responses than those in static cultures. The in vitro vaccination system responded to various premanufactured vaccines, protein antigens, and antigen combinations. In particular, a multivalent in vitro immunization with three phylogenetically distant H3N2 influenza strains showed evidence for broader B cell activation and induced higher antibody cross-reactivity than combinations with more related strains. Moreover, we demonstrate the capacity of our in vitro model to generate de novo humoral immune responses to a model antigen.

Discussion: Perfusion-cultured tonsil tissue may be a valuable human in vitro model for immunology research with potential application in vaccine candidate selection.

Keywords: antibodies; bioreactor; human; in vitro model; influenza; tonsil; vaccines.

MeSH terms

  • Antibodies, Viral / immunology
  • B-Lymphocytes / immunology
  • Bioreactors*
  • Humans
  • Immunogenicity, Vaccine
  • Influenza A Virus, H3N2 Subtype / immunology
  • Influenza Vaccines* / immunology
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control
  • Palatine Tonsil* / immunology
  • Tissue Culture Techniques
  • Vaccination

Substances

  • Influenza Vaccines
  • Antibodies, Viral

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was funded by the Uniscientia Foundation and supported by the SNSF (310030_192440) (both to CB).